Physician compensation is rising faster in cardiology than any other specialty. Still, considering how demanding the job is, many cardiologists feel underpaid.
Nearly 700 bottles of a popular ACE inhibitor are being recalled after it failed an Organic Impurities Test. The drug was manufactured in India and then distributed by New Jersey-based Rising Pharma Holdings.
Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Performing TAVR on a patient with bicuspid AS can be challenging. Transcatheter aortic root tricuspidization may represent a new treatment strategy for these patients, according to a new first-in-human trial.
In new Neiman Health Policy Institute research, scientists explored the use of artificial intelligence to aid in diagnosing PE on CTPA, with “AI-informed radiologists" scoring high marks.
The TowerBrook Capital-backed breast imaging provider announced the latest openings on May 11, with new centers in Houston and Doylestown, Pennsylvania.
This leaves only about 18% of docs practicing in physician-owned settings as of Jan. 1, with corporations employing an additional 48,000-plus docs over the past two years.
Private-equity acquisitions of primary-care provider practices neither alter hospitalization rates nor affect acute-care outcomes, according to new research out of Brown University.
Epic makes the list with its enterprise inpatient EHR and related platforms. So does PCC, aka Physician’s Computer Company, which supplies pediatric-specific ambulatory EHR and practice-management products and services.
Physician compensation is rising faster in cardiology than any other specialty. Still, considering how demanding the job is, many cardiologists feel underpaid.
Nearly 700 bottles of a popular ACE inhibitor are being recalled after it failed an Organic Impurities Test. The drug was manufactured in India and then distributed by New Jersey-based Rising Pharma Holdings.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
